SCHEMBL109668

SCHEMBL109668

CCCC[Sn](CCCC)(CCCC)c1ncccn1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 3/20 0.34
CYP19A1 P11511 2/20 0.34
CYP2C9 P11712 2/20 0.34
CYP2C19 P33261 2/20 0.34
CYP1A2 P05177 1/20 0.34
KDM4E B2RXH2 2/20 0.32
LMNA P02545 2/20 0.32
HTT P42858 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
NPC1 O15118 2/20 0.32
USP2 O75604 1/20 0.32
ALOX15 P16050 1/20 0.32
ALOX12 P18054 1/20 0.32
HSP90AA1 P07900 1/20 0.32
RAB9A P51151 1/20 0.32
ALDH1A1 P00352 1/20 0.31
POLB P06746 1/20 0.31
KMT2A Q03164 1/20 0.31
CYP3A4 P08684 2/20 0.31
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyrimidine SCHEMBL6585223 0.90 TDP1 (0.33) CYP2D6CYP19A1CYP2C9CYP2C19CYP1A2
Dioxane SCHEMBL4259401 0.89 MAPK1 (0.32) CYP1A2LMNAUSP2ALDH1A1
SCHEMBL29893529 0.78 KDM4E (0.33) KDM4EALDH1A1
SCHEMBL11064389 0.78 TLR8 (0.37) CYP2D6CYP3A4
SCHEMBL28893694 0.77 CYP1A2 (0.32) CYP2D6CYP19A1CYP2C9CYP2C19CYP1A2
SCHEMBL5719734 0.77 L3MBTL1 (0.32) CYP1A2KDM4ELMNASMN1; SMN2NPC1
SCHEMBL17584302 0.77
SCHEMBL22613548 0.77 ALOX15 (0.33) ALOX15ALDH1A1POLBKMT2A
SCHEMBL28505 0.75 CYP1A2 (0.41) CYP2D6CYP19A1CYP2C9CYP2C19CYP1A2
SCHEMBL29390052 0.75 CYP1A2 (0.41) CYP2D6CYP19A1CYP2C9CYP2C19CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114049981-B Silver tin nano material conductive silver paste and application thereof to vacuum glass 四川英诺维新材料科技有限公司 2024-03-15 CN claimed
CN-114049981-A Silver-tin nano material conductive silver paste and application thereof to vacuum glass 重庆英诺维节能环保科技有限公司 2022-02-15 CN claimed
WO-2026106499-A1 OREXIN RECEPTOR ANTAGONISTS: 2-AZABICYCLIC COMPOUNDS BIAL - PORTELA & CA., S.A. (PT) 2026-05-21 WO disclosed
CN-115835909-B Cannabinoid receptor type 2 (CB 2) modulators and uses thereof 泰昂治疗公司 2026-05-15 CN disclosed
EP-4741392-A1 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF Shenzhen TargetRx Co., Ltd. (CN) 2026-05-13 EP disclosed
CN-122029155-A Heterocyclic compound and harmful arthropod control composition containing same 住友化学株式会社 2026-05-12 CN disclosed
CN-122029166-A Condensed cyclic compound and harmful arthropod control composition containing the same 住友化学株式会社 2026-05-12 CN disclosed
US-20260125357-A1 LACTATE ENHANCING COMPOUNDS AND USES THEREOF GLIAPHARM SA (CH) 2026-05-07 US disclosed
EP-4735114-A1 SUBSTITUTED THIENO [3,2-B]PYRIDINES AS INHIBITORS OF PROTEIN KINASES Masarykova Univerzita (CZ) 2026-05-06 EP disclosed
EP-4142732-B1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2026-04-22 EP disclosed
US-12606522-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives ORSOBIO, INC. (US) 2026-04-21 US disclosed
EP-0925288-A1 PROCESS OF PRODUCTION OF 4-SUBSTITUTED-3-HALOGENO-1,4-BENZOXAZEPINE DERIVATIVE AND SALTS THEREOF SUNTORY LIMITED (JP) 1999-06-30 EP disclosed
EP-0912559-A1 FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 1999-05-06 EP disclosed
WO-1999003847-A1 PROCESS OF PRODUCTION OF 4-SUBSTITUTED-3-HALOGENO-1,4-BENZOXAZEPINE DERIVATIVE AND SALTS THEREOF SUNTORY LIMITED (JP) 1999-01-28 WO disclosed
WO-1998030560-A1 QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY, PARTICULARLY IN THE TREATMENT OF BEGNIN PROSTATIC HYPERPLASIA PFIZER LIMITED (GB) 1998-07-16 WO disclosed
WO-1998002434-A1 FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 1998-01-22 WO disclosed
WO-1997046554-A1 3-PYRIDYLOXYMETHYL HETEROCYCLIC ETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION ABBOTT LABORATORIES (US) 1997-12-11 WO disclosed
US-5656754-A REACTING AN ALLENYL-B-LACTAM COMPOUND WITH AN ORGANOTIN COMPOUND OTSUKA KAGAKU KABUSHIKI KAISHA (JP) 1997-08-12 US disclosed
EP-0755930-A1 BENZOXAZEPINE DERIVATIVES, SALTS THEREOF, AND DRUGS CONTAINING THE SAME SUNTORY LIMITED (JP) 1997-01-29 EP disclosed
EP-0623622-A1 PROCESS FOR PRODUCING CEPHEM COMPOUND OTSUKA KAGAKU KABUSHIKI KAISHA (JP) 1994-11-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125357-A1 LACTATE ENHANCING COMPOUNDS AND USES THEREOF LDHA, PC, LDHB CYP2D6 1064/4885CYP19A1 1902/4885CYP2C9 1631/4885
US-12606522-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives NR3C2, NR5A1, SRD5A2 CYP2D6 92/4885CYP19A1 368/4885CYP2C9 418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.